Fosamax and Osteonecrosis of the Jaw: Examining the Causal Link

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

The legacy of general health and science information has long provided a foundational framework for public understanding of medical risks and therapeutic interventions. Within this broad context, discussions of medication side effects and bone health have been standard, yet they typically remain anchored in population-level guidance rather than individual exposure scenarios. As we pivot from this general heritage toward a more specific occupational concern, the focus narrows to the relationship between pharmaceutical exposure and localized tissue response. In the domain of mass production, where workers may handle or be exposed to active pharmaceutical ingredients, the question of causation becomes operationally critical. The transition from general health literacy to occupational exposure concern requires acknowledging that routine clinical warnings—such as those associated with bisphosphonate therapy—may not fully capture the risk profile for individuals with repeated, direct contact with these compounds. This shift emphasizes the need to evaluate exposure pathways, duration, and concentration in manufacturing environments, rather than relying solely on patient-oriented safety data. The bridge concept thus moves from a passive receipt of health information to an active assessment of workplace exposure, setting the stage for a targeted inquiry into whether such occupational contact elevates the risk of adverse outcomes like osteonecrosis of the jaw.

Bridging General Knowledge to Specific Risk Assessment

The transition from general health literacy to occupational exposure concern requires acknowledging that routine clinical warnings—such as those associated with bisphosphonate therapy—may not fully capture the risk profile for individuals with repeated, direct contact with these compounds. This shift emphasizes the need to evaluate exposure pathways, duration, and concentration in manufacturing environments, rather than relying solely on patient-oriented safety data. The bridge concept thus moves from a passive receipt of health information to an active assessment of workplace exposure, setting the stage for a targeted inquiry into whether such occupational contact elevates the risk of adverse outcomes like osteonecrosis of the jaw.

Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The question of whether Fosamax causes ONJ requires careful examination of clinical evidence, mechanistic pathways, and risk factors. Clinical evidence from FDA-approved labeling indicates that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling explicitly states: 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This association is further supported by labeling for Fosamax Plus D, which notes that known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors

Mechanistic pathways linking Fosamax to ONJ are grounded in the drug's pharmacology as a bisphosphonate that inhibits bone resorption. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates like Fosamax suppress osteoclast activity, which can impair bone remodeling and healing, particularly in the jaw where high bone turnover occurs. This suppression may lead to microdamage accumulation and reduced vascularity, predisposing the jaw to necrosis, especially after dental procedures or infection. Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse event, its incidence in clinical trials was not statistically different from placebo, indicating that other factors may contribute.

Adequacy of Warnings and Causation Considerations

Adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's labeling under Section 5.4, which explicitly describes the condition, associated risk factors, and recommendations. The labeling advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This warning provides clinicians with guidance to mitigate risk, though the optimal duration of use for Fosamax has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve evaluating individual risk factors. The presence of known risk factors such as cancer, chemotherapy, corticosteroids, poor oral hygiene, and dental procedures increases the likelihood of ONJ in Fosamax users. However, the drug's labeling notes that ONJ can occur spontaneously, and the temporal relationship between drug initiation and symptom onset can vary widely. For patients who develop ONJ while on Fosamax, the drug's discontinuation may lead to symptom relief, but recurrence upon rechallenge suggests a causal role in susceptible individuals. In summary, Fosamax is associated with ONJ, as documented in FDA-approved labeling and supported by mechanistic understanding of bisphosphonate effects on jawbone. The risk is influenced by duration of exposure, dental procedures, and other comorbidities. Warnings in the labeling are adequate to inform clinical decision-making, but causation in individual cases requires careful assessment of risk factors and temporal patterns.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does Fosamax cause osteonecrosis of the jaw?

Yes, Fosamax (alendronate) is associated with osteonecrosis of the jaw (ONJ) as documented in FDA-approved labeling. The labeling states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the incidence in clinical trials was similar to placebo, indicating that other risk factors such as dental procedures, cancer, and corticosteroids contribute.

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer, chemotherapy, corticosteroids, angiogenesis inhibitors, poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

How long after starting Fosamax can ONJ occur?

The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, but some may have recurrence if rechallenged.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.